Physicochemical and structural properties of proteins used as active pharmaceutical ingredients of biopharmaceuticals are determinant to carry out their biological activity. In this regard, the assays intended to evaluate functionality of biopharmaceuticals provide confirmatory evidence that they contain the appropriate physicochemical properties and structural conformation. The validation of the methodologies used for the assessment of critical quality attributes of biopharmaceuticals is a key requirement for manufacturing under GMP environments. Herein we present the development and validation of a flow cytometry-based methodology for the evaluation of adalimumab's affinity towards membrane-bound TNF␣ (mTNF␣) on recombinant CHO cells. This in vitro methodology measures the interaction between an in-solution antibody and its target molecule onto the cell surface through a fluorescent signal. The characteristics evaluated during the validation exercise showed that this methodology is suitable for its intended purpose. The assay demonstrated to be accurate (r 2 = 0.92, slope = 1.20), precise (%CV ≤ 18.31) and specific (curve fitting, r 2 = 0.986-0.997) to evaluate binding of adalimumab to mTNF␣. The results obtained here provide evidence that detection by flow cytometry is a viable alternative for bioassays used in the pharmaceutical industry. In addition, this methodology could be standardized for the evaluation of other biomolecules acting through the same mechanism of action.
Introduction
Biopharmaceuticals are heterogeneous molecules manufactured under stringent quality controls intended to ensure their batch-to-batch consistency. Accordingly, regulatory guidelines, indicate the relevant characteristics or attributes that need to be evaluated to determine their quality. In this regard, different analytical methodologies are employed for the evaluation of critical quality attributes (CQAs) with respect to identity, structure, heterogeneity, purity and functionality. The evaluation of functionality in bioassays is a fundamental part of quality assessment of biopharmaceuticals [1] because it provides confirmation of the appropriateness of other physicochemical and structural CQAs; additionally, functionality assays to properly evaluate its mechanism of action. However, the development, standardization and implementation of bioassays is a challenging task because they depend on the response of living organisms (i.e. cultured cells), the use of critical reagents, and other uncontrollable sources of variability that affect the system's performance [1] [2] [3] [4] .
Bioassays must be capable to reproduce in vitro the mechanisms of action by which a biomolecule is capable to achieve its biological activity in patients. Additionally, bioassays should incorporate a reliable technique that reveals the interaction between the biomolecule and its target, commonly colorimetric, luminiscent or fluorometric signals [5] . Accordingly, the development of bioassays requires a deep understanding of the mechanisms of action of the biomolecules under study; this is important during the design of the assay, because allows defining the critical characteristics to be evaluated based and helps to select the most appropriate analytical approaches for their assessment [6] .
Once the characteristics to evaluate and the approach for assessment have been defined, the experimental conditions of the bioassay must be standardized, and then should be validated to demonstrate that it is suitable for its intended purpose [7] [8] [9] . The validation exercise must be focused on the evaluation of characteristics that warranty that the assay is robust under the experimental conditions in which will be performed. In general, the characteristics evaluated during a validation exercise include specificity, accuracy, precision, sensitivity and system suitability [1, 7, 9, 10] . However, the validation exercise of bioassays and the stringency to evaluate each characteristic will depend on the nature of each assay, the knowledge gained during its development and standardization, as well as its intended purpose (e.g. R&D, Manufacturing, Quality Control, Batch Release, or Biosimilarity analysis).
In this article, we present the development and validation of a bioassay designed to evaluate the interaction of adalimumab and its target, tumor necrosis factor alpha (TNF␣), for this purpose, we used recombinant CHO cells that express TNF␣ bound to their membrane (mTNF␣). TNF␣ is a pleiotropic inflammatory cytokine central regulator of inflammation which is responsible of chronic diseases such as rheumatoid arthritis, ankylosing spondilitys and Crohn's disease [11] . Adalimumab is a human anti-human TNF␣ therapeutic monoclonal antibody produced by phage display which has been successfully employed in the treatment of several TNF␣ mediated diseases [12] [13] [14] .
Interactions between adalimumab and TNF␣ have been well described at a molecular level. It has been reported that adalimumab binds to TNF␣ with a relative higher affinity than other anti-TNF␣ molecules such as Etanercept and Infliximab [15] . In addition, crystallography studies showed that adalimumab prevents ligand from binding to TNFR2, inhibits ligand-receptor binding, and blocks TNFR activation [16] .
It is well known that native transmembrane TNF␣ (mTNF␣) of organisms is involved in the inflammatory response acting as a bipolar molecule that transmits signals, either as a ligand, or mediating reverse signals into mTNF-expressing cells [15, 17] . On the other hand, it has been reported that anti-TNF␣ antibodies exert their main therapeutic effect by binding to mTNF␣ to form stable immune complexes [17] .
Despite the interaction of adalimumab and TNF␣ has been widely studied from a clinical research perspective, the information on bioassays designed to evaluate binding in vitro as routine tests for quality control purposes in the pharmaceutical industry is more modest.
The bioassay presented herein resorts to flow cytometry to evidence the binding of adalimumab to mTNF␣ of a recombinant CHO cell line through a fluorometric signal. Flow cytometry has been widely employed to analyze phenotypic characteristics of cells based on the Coulter principle coupled to a detection system that measures how the cell or particle scatters incident laser light and emits fluorescence [18] . Despite this technology has been applied as an identity method of cells, it has been little used for obtaining data to build dose-response curves.
In order to determine the suitability of the bioassay we evaluated its performance through a validation exercise that included the assessment of specificity, accuracy, precision and system suitability. The validation exercise was designed and conducted according to the USP 1033 Biological Assay Validation Chapter [1] and the ICH Validation Guideline Q2(R1) [9] . The validation of the assay ensures its robustness to be used as an in vitro pre-clinical test of biological activity of adalimumab for batch release, functional characterization or biocomparability purposes.
Materials and methods

Materials
Engineered CHO-K1 cells expressing membrane-bound TNF␣ (mTNF␣ cells) were acquired from PROMEGA (Madison, WI, USA). RPMI-1640 medium (ATCC, Manasas, VA, USA). Fetal Bovine Serum (Gibco, GI, NY, USA), PBS buffer (Gibco, GI, NY, USA), Trypsin Try-PLE Select 1X (Gibco, GI, NY, USA), EDTA (Ambion), BD cytofix solution (BD Biosciences, San Jose, CA, USA), IgG Anti-human PE (ebisocience), IgG Anti-TNF␣ APC (BD pharmingen). Adalimumab, 40 mg/0.8 mL solution for injection in pre-filled pen, batch 51073LX01, was acquired from Abbvie Inc.
Preparation of cells
mTNF␣ cells were routinely grown in RPMI medium containing 10% Fetal Bovine Serum (FBS) at 37 • C, 5% CO 2 . This is a stable cell line developed to be ready to use, and do not require selective pressure nor further passages to express mTNF␣ consistently, this ensures reproducibility of assays. The cells were harvested at 80% of confluence. The harvested cells were centrifuged, washed and resuspended in PBS. Viable cells were counted by the trypan blue exclusion method [19] prior to be prepared with BD Cytofix TM Fixation Buffer (according to the manufacturer's protocol) for subsequent staining and cytometric analysis. Finally, the concentration of cells was adjusted to 4 × 10 6 cells/mL with PBS + 1% horse serum (washing buffer).
Staining of cells for flow cytometry
50 L of cells suspension prepared in the previous step (containing 200,000 cells) were dispensed into 1.5 mL Eppendof tubes. Different concentrations of either, adalimumab or antibody anti-TNF␣ (APC), were added to the tubes containing the cells as separate treatments, and then were incubated 1 h at 4 • C. The cells were washed with wash buffer and the pellet was recovered by centrifugation. Then, the cells exposed to adalimumab were resuspended and added with 50 L of PE anti-human IgG Fc (1:500) and incubated during 45 min at 4 • C. Finally, the cells were washed twice with wash buffer and stored at 4 • C until they were analyzed in an Aria III flow cytometer (BD Biosciences, San Jose, CA, USA). mTNF␣ cells were gated based on single events and homogeneus morphology according to size and granularity by the Forward Scatter (FSC) and Side Scatter (SSC) respectively. Unstained cells were regarded as controls to determine the autofluorescence of the cells. Cells incubated only in the presence of PE anti-human IgG Fc (without of adalimumab) or in the presence of adalimumab with an isotype control antibody were used as controls to evaluate unspecific binding.
Detection of adalimumab-mTNF˛ complex
The stained cells were analyzed in FACSAria III flow cytometer. The binding of adalimumab to mTNF␣ was evaluated by the increase of the Median Fluorescence Intensity (MFI) of the fluorochrome conjugated to the anti-human Fc antibody. Then the fold increase was calculated as MFI of concentration of adalimumab/MFI without adalimumab control.
Validation
The parameters to be fulfilled for validation were established according to the ICH guideline Q2(R1) [9] and the USP 1033 Biological Assay Validation Chapter [1] considering the parameters below. The acceptance criteria for each evaluated parameter of the validation exercise was established according to the method capabilities observed during the standardization stage and its intended purpose, which is to evaluate in vitro the binding of adalimumab to mTNF␣ express on recombinant CHO cells for QC purposes.
Specificity (Curve fitting)
Specific recognition and binding of adalimumab to mTNF␣ was tested against matrix components (excipients). A dose-response curve (model curve) constructed from the Fold increase in MFI values generated from independent triplicates at 9 dilution levels of adalimumab (in a range from 3.2 to 700 ng/mL) with respect to the matrix prepared under the same dilution scheme and replicates. In this context, specificity is given by the fitting of the model curve into the assay data through a non-linear regression model. Curve fitting was tested under four or five-parameter logistic models (4PL and 5PL, respectively) using the software Graph Pad Prism.
Accuracy (dilutional linearity)
Accuracy several factors such as buffer components and sample matrix can impact on binding of antibodies in bioassays, hence influence the accuracy of the method. Accordingly, accuracy is usually measured through dilutional linearity that accounts for such variations. We evaluated accuracy at all the dilution levels of the dose-response curve in a concentration range from 60% to 140%. The pre-defined acceptance criteria for acceptable linearity was r 2 ≥ 0.90 and slope in a range from 0.80 to 1.25.
Precision
The precision describes how the method is capable to reproduce independent results with variations within an acceptable given distribution of single measurements. We estimate precision through the coefficient of variation (CV) from three independent replicates at the nine concentration levels of the dose-response curve. The pre-defined acceptance criteria were CV ≤ 20% among replicates at all the evaluated levels.
System suitability
According to the manufacturer's guides, before setting up an experiment, we run a performance check using the Cytometer Setup and Tracking (CST) application (BD TM ). This performance check ensures that the cytometer is performing consistently for automatic characterization, tracking, and measurement acquisi- tion. Additionally, the system suitability should be determined by specificity using dye controls capable to unambiguously identify specific populations. In this work the system suitability was determined considering the capability of the flow cytometer to detect a differential dose-response among the samples containing adalimumab-mTNF␣ complex and the negative controls. The parameters evaluated were CV (from precision) and r 2 of the doseresponse curve within the concentration levels range.
Results and discussion
Development of the bioassay
Expression and bound of TNF˛ to cell membrane
The first step was to demonstrate that the recombinant cell line was capable to express TNF␣ onto their cell membrane (mTNF␣). For this purpose we analyzed the cell line to determine size and granularity using forward scatter (FSC) and side scatter (SSC) respectively (Fig. 1A and B) . Our results confirmed that the detected events corresponded to CHO-K1 cells. Additionally, the expression of TNF␣ onto cell membrane was determined through median fluorescence intensity (MFI) from APC (Fig. 1C) . These results confirmed that under our experimental conditions, the recombinant CHO-K1 cells were capable to express and bound TNF␣ to their membrane.
Establishment of adalimumab-mTNF˛ complex
We selected an anti-human Fc antibodies conjugated to PE in order to determine the establishment of the adalimumab-mTNF␣ complex. The anti-Fc antibody conjugated to PE exhibited a displacement in MFI with respect to the controls, which is indicative of specific recognition of the Fc portion of adalimumab (Fig. 1D) . These results confirmed that the biological model, along with the detection method by flow cytometry, were appropriate to evaluate binding of adalimumab to its target in vitro.
Standardization
Based on our previous experience developing cell-based assays [20, 21] we adjusted the biological system to 2 × 10 5 cells to evaluate the dose-response ratio of adalimumab binding to mTNF␣ through the MFI. We observed a dose-response behavior denoted as displacements of MFIs obtained from cells exposed to different dilution levels of adalimumab in a range from 3 to 700 ng/mL ( Fig. 2A) . The curve constructed from these fold increases in MFI values showed an asymmetric dose-response shape with a shorter tail at the upper end (Fig. 2B ).
Validation
Specificity (Curve fitting)
It was observed that samples prepared at different concentrations of adalimumab exhibited a concentration-dependent MFI response, while the negative controls did not exhibit any signal different to cell auto fluorescence. These results showed that there was no interference of the matrix and the signal from the samples is the result of the specific interaction between adalimumab and mTNF␣ (Fig. 3A) .
In most of bioassays, the effect of the concentration of the analyte on the biological response traditionally results in a sigmoidal shape which fits to the four-parameter logistic model (4PL). However, in some cases, the data may not result in sigmoidal doseresponse curves [22] . In such circumstances, it is recommended to regard asymmetry into the mathematical model for curve fitting [22] . The five-parameter logistic model (5PL) invokes the same parameters of the 4PL equation, plus an asymmetry factor which provides a better fit when the response curve is not symmetrical [22] . Despite, in various experiments 5PL exhibits a better fit of asymmetrical curves; in this work, we observed that the both, 4PL and 5PL, exhibited similar results in the goodness to fit test (Table 1) . This means that for this particular case, asymmetry is negligible to fit of the model curve to the true curve. Accordingly, the validation was carried out using 4PL fitting and the results complied with the pre-defined acceptance criteria (Table 2) .
Accuracy
Accuracy estimated by dilutional linearity of the effect of adalimumab concentration (log) on the MFI at five dilution levels (from 60 to 140%) showed a correspondence between nominal and measured potency with a correlation coefficient r 2 = 0.9 (Fig. 3B) .
Precision
The coefficient of variation (% CV) among replicates was < 20% at all the evaluated levels (Table 3) , which complies with the pre- The dose-response curve of the detection of the positive sample should exhibit a fold increase in MFI related to the log concentration of adalimumab of the positive samples in the range of 3.2-700 ng/mL.
The dose response of the positive samples exhibited a fold increase at all concentration levels that fitted to 4PL (r 2 = 0.986 to 0.997).
The negative controls should not exhibit a fold increase in MFI.
MFI of negative controls did not show a fold increase and did not fit to 4PL (r 2 = 0.125). defined acceptance criteria. It was observed that the variation increases as the samples are diluted, however, this variation did not affect precision within the evaluated range.
System suitability
It was observed that the samples containing adalimumabmTNF␣ complexes exhibited a dose-response behavior that fitted to a non-linear mathematical model, while the response of negative controls was mainly flat. The CV among samples was < 0.20, while r 2 for the dose-response curve was > 0.9. These results are indicative in one hand, that the bioassay is capable to exert a differential behavior of the positive samples with respect to the negative controls, and in the other hand that the flow cytometry instrument is capable to detect accurately such differences.
Conclusions
Flow cytometry has been employed for different purposes related to cell characterization and functionality. The results obtained here show that flow cytometry is also an appropriate alternative as a detection method in bioassays [21, 23] . The advantages of using flow cytometry in bioassays rely on the automation, sensitivity, dying controls and self-calibration that allow obtaining accurate and consistent measurements. On the other hand, the validation exercise demonstrated that the developed bioassay is suitable for the evaluation of binding of adalimumab to mTNF␣ expressed by rCHO cells. Additionally, we observed that despite 5PL model is highly recommended to fit non-sigmoidal curves, one must be cautious when choosing this model since unexpected results could arise due to assumptions or constraints of the model and software. The collective results from the development and validation of this bioassay, suggest that it could be implemented as a routine methodology in QC laboratories for batch release, or as a test for characterization and biocomparability of adalimumab. Actually, the experimental conditions could be standardized for the evaluation of other biomolecules acting through the same mechanism of action. The information from this validation exercise contributes to expand the applications of flow-cytometry for bio- drugs characterization and for the demonstration of comparability of biosimilars.
